RXII incredible breast cancer vaccine results.
DNDN vaccine extended life expectancy for an average 2 months. The Neuvax results seem a lot better to me.
All study groups showed big reductions even though most groups did not have optimal dose.

The Optimal dose group results were eye popping. Recurrance rate dropped from 14.5% to 2.7% for patients that had the vaccine.

Results: The trials have enrolled 188 patients; 109 (58%) HLA-A2/A3+ patients assigned to the vaccination group (VG), and 79 (42%) HLA-A2/A3- patients assigned to the control group (CG). The only significant prognostic difference between the groups was more ER/PR negativity in the VG (p=0.04). With 24 mo f/u complete in all patients, a 24 mo landmark analysis revealed a recurrence rate (RR) of 6.5% in the VG and 14.5% in the CG (p=0.08). At a median f/u of 57 mos, there is a persistent, though not statistically significant, 35% relative risk reduction in recurrences in the VG. Importantly, due to trial design, 72 patients received less then what was determined to be the optimal biologic dose.
In subset 24 mo landmark analyses, patients who benefit most from vaccination were NP (11.5% vs 20.9% RR in VG vs CG, p=0.26), had HER2 IHC 1+, 2+ (7.8% vs 23.5% RR, p=0.06) or grade 1,2 (1.6% vs 16.3% RR, p=0.01) tumors, were optimally dosed (2.7% vs 14.5% RR, p=0.10), and boosted (0% vs 8.5% with early recurrences prior to booster program omitted, p=0.03).

Conclusions: The E75 vaccine may prevent breast cancer recurrence in subsets of patients. To investigate this, a phase III trial with optimal dosing and booster inoculations is being initiated for NP, HER2 IHC 1+,2+ patients.

RXII:NASDAQ ($.98) has promising cancer vaccine, SPA status and a potential $5 billion market.

RXII has been undiscovered but not for long. Will present 3 year survival data at ASCO.

RXII has $20 MM cash and $30 MM market cap, meaning the market is valuing its technology at $10 million.

Other junior biotechs in the cancer vaccine space like AGEN:NASDAQ have minimum $100 MM ++ market caps.
GNVC rose to a $250 Million market cap a few years ago with a Cancer vaccine.

About NeuVax(TM) (E75)

NeuVax consists of the E75 peptide derived from HER2 combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase II trial, which achieved its primary endpoint of disease free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for a Phase III clinical trial in the adjuvant setting for women with low-to-intermediate HER2+ status.

According to the National Cancer Institute, over 200,000 women in the U.S. are diagnosed with breast cancer annually. Of these women, about 75% test positive for Human Epidermal growth factor Receptor 2 (IHC 1+, 2+ or 3+). Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin(R) (trastuzumab; Roche-Genentech) which had revenues of over $5 billion in 2010. NeuVax targets the remaining 50% of HER2 positive patients (HER2 1+ and 2+) who achieve remission with current standard of care, but have no available HER2 targeted adjuvant treatment options to maintain their disease free status.

RXII:NASDAQ ($.98) has one of the most promising cancer vaccines, with SPA status and a potential $5 billion market.
I called OXGN. RXII could be next.
RXII has been undiscovered but not for long. Will present 3 year survival data at ASCO.

RXII has $20 MM cash and $30 MM market cap, meaning the market is valuing its technology at $10 million.

Other junior biotechs in the cancer vaccine space like AGEN:NASDAQ have minimum $100 MM ++ market caps.
GNVC rose to a $250 Million market cap a few years ago with a Cancer vaccine.

About NeuVax(TM) (E75)

NeuVax consists of the E75 peptide derived from HER2 combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase II trial, which achieved its primary endpoint of disease free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for a Phase III clinical trial in the adjuvant setting for women with low-to-intermediate HER2+ status.

According to the National Cancer Institute, over 200,000 women in the U.S. are diagnosed with breast cancer annually. Of these women, about 75% test positive for Human Epidermal growth factor Receptor 2 (IHC 1+, 2+ or 3+). Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin(R) (trastuzumab; Roche-Genentech) which had revenues of over $5 billion in 2010. NeuVax targets the remaining 50% of HER2 positive patients (HER2 1+ and 2+) who achieve remission with current standard of care, but have no available HER2 targeted adjuvant treatment options to maintain their disease free status.

TISA 6 forward PE 20% growth booming sector $6 target

TISA announced $.10 non GAAP EPS in Q1 2011. The CEO is forecasting 20% - 25% growth for 2011, so $.40 annual EPS for 2011 is very conservative.

TISA trades at a forward PE ratio of 6 compared to the Industry average of 27. If TISA traded at even HALF the sector average it would be $6.

TISA is a player in one of the highest profile tech sectors, mobile payments.
TISA has far better fundamemtals than MITK.OB , which in the same space and trades at 4 x the market cap of TISA.

The most successful U.S. hedge fund, Renaissance Capital, owns TISA.
Renaissance has an army of engineers and MBA's scouring for undervalued stocks.

TISA has slashed costs to the bone. Selling and administrative expenses have fallen 50% from 2008 levels.

TISA has a tightly held 5.8 Million float.

In short, TISA has all the ingredients to go much higher in a very short time frame.

HIGHLIGHTS:

- Profitable.
- 5.8 MM float.
- $27 MM market cap
-Major players in sector (MITK) have gained up to 1000% while TISA is still under the radar.
- Frequently mentioned as acquisition candidate because of industry consolidation.

TISA 6 forward PE 20% growth booming sector $6 target

TISA announced $.10 non GAAP EPS in Q1 2011. The CEO is forecasting 20% - 25% growth for 2011, so $.40 annual EPS for 2011 is very conservative.

TISA trades at a forward PE ratio of 6 compared to the Industry average of 27. If TISA traded at even HALF the sector average it would be $6.

TISA is a player in one of the highest profile tech sectors, mobile payments.
TISA has far better fundamemtals than MITK.OB , which in the same space and trades at 4 x the market cap of TISA.

The most successful U.S. hedge fund, Renaissance Capital, owns TISA.
Renaissance has an army of engineers and MBA's scouring for undervalued stocks.

TISA has slashed costs to the bone. Selling and administrative expenses have fallen 50% from 2008 levels.

TISA has a tightly held 5.8 Million float.

In short, TISA has all the ingredients to go much higher in a very short time frame.

HIGHLIGHTS:

- Profitable.
- 5.8 MM float.
- $27 MM market cap
-Major players in sector (MITK) have gained up to 1000% while TISA is still under the radar.
- Frequently mentioned as acquisition candidate because of industry consolidation.

DSCO is next IXGN cheapest Biotech on NASDAQ. $3 soon:
-Tiny 21 Million float.

-$27 million cash or $1.1 per share.

-DSCO has resolved manufacturing issues and is ready to file a New Drug Application in a vew months for a drug with a potential $1.8 billion market.
Back out the cash, the market is valuing DSCO at $30 million, the cheapest valuation by miles for any stock with pending drug application.

- The sector is hot and will stay on fire until ASCO.

If you misssed OXGN, DSCO is next.

BLTI could pop 30% Monday on earnings

Laser dentistry stock BLTI has been hottest stock on NASDAQ this year.
They already guided for a 136% increase in sales for Q1 which sparked a rally to $6.92. Now $5.33.

http://finance.yahoo.com/news/BIOLASE-Announces-That-It-iw-2485159527.html?x=0&.v=1

Other facts
-150% sales increase for 2011 forecast to $65 million.
-Over 250 patents
-In final stages for licensing agreements according to presentation filed yesterday.

They report on Monday before the market opens.
Only 22 MM float.

BLTI could be next ATEA Monday.

Laser dentistry stock BLTI has been hottest stock on NASDAQ this year.
They already guided for a 136% increase in sales for Q1 which sparked a rally to $6.92. Now $5.33.

http://finance.yahoo.com/news/BIOLASE-Announces-That-It-iw-2485159527.html?x=0&.v=1

Other facts
-150% sales increase for 2011 forecast to $65 million.
-Over 250 patents
-In final stages for licensing agreements according to presentation filed yesterday.

They report on Monday before the market opens.

You realize that it is impossible for a government that can print money to defaut, don't you?

OXGN + 30% 5 MM float, Phase 3 drugs
OXGN has by far the lowest market cap of any Phase 3 drug stock. At the $2.25 closing price, OXGN had a $12 Million market cap with a very promising drug in Phase 3.

Every other biotech stock I follow with a drug this far advanced in the regulatory process has a market cap of $50 - $100 million. Not only is ZYBRESTAT promising for thyroid cancer, but it has potential in ovarian cancer and non-small cell lung cancer (NSCLC).

Want a comparable to provide a reasonable valuation metric? CYCC had a $100 million market cap last year because of a NSCLC drug candidate.

Even in a worst case scenario and OXGN issues another 6 Million shares, it would still have a TINY 12 Million float and Huge upside. Thats why it reminds me of RPRX. RPRX also had a tiny float, but went UP after it issued a few million shares as it STILL had a tiny float, and financing worries were alleviated.

Enjoy. $3.50 - $4 very soon.

OXGN + 30% can go to $10 quite easily: 5 MM float, Phase 3 drugs
OXGN has by far the lowest market cap of any Phase 3 drug stock. At the $2.25 closing price, OXGN had a $12 Million market cap with a very promising drug in Phase 3.

Every other biotech stock I follow with a drug this far advanced in the regulatory process has a market cap of $50 - $100 million. Not only is ZYBRESTAT promising for thyroid cancer, but it has potential in ovarian cancer and non-small cell lung cancer (NSCLC).

Want a comparable to provide a reasonable valuation metric? CYCC had a $100 million market cap last year because of a NSCLC drug candidate.

Even in a worst case scenario and OXGN issues another 6 Million shares, it would still have a TINY 12 Million float and Huge upside. Thats why it reminds me of RPRX. RPRX also had a tiny float, but went UP after it issued a few million shares as it STILL had a tiny float, and financing worries were alleviated.

Enjoy. $3.50 - $4 very soon.

ZHNE poised to triple (Seeking Alpha) http://seekingalpha.com/article/265364-z...

ZHNE is the best buy on NASDAQ IMO.

-Low float, cash flow positive, turning GAAP profitable in second half of the year.

-Trades at a Price/Sales ratio of 0.6 compared to Industry average of 2.5.

-Traded at $15 - $20 range in 2006.

Major players in sector (ALU, TXCC) have gained up to 300% while ZHNE is still under the radar.

-If you back out the $1.70 per share working capital, ZHNE trades at $.70
http://finance.yahoo.com/q/bs?s=ZHNE+Bal...

In short, ZHNE has all the ingredients to go much higher in a very short time frame.

ZHNE poised to triple (Seeking Alpha) http://seekingalpha.com/article/265364-z...

ZHNE is the best buy on NASDAQ IMO.

-Low float, cash flow positive, turning GAAP profitable in second half of the year.

-Trades at a Price/Sales ratio of 0.6 compared to Industry average of 2.5.

-Traded at $15 - $20 range in 2006.

Major players in sector (ALU, TXCC) have gained up to 300% while ZHNE is still under the radar.

-If you back out the $1.70 per share working capital, ZHNE trades at $.70
http://finance.yahoo.com/q/bs?s=ZHNE+Bal...

In short, ZHNE has all the ingredients to go much higher in a very short time frame.

ADAT:NASDAQ $1.47 +$.22 $5 Target
Noone knows the Veteran Administration contract is $122 Million OK, all you math geniuses out there, you better take a close look at this filing because I think it says a lot IF YOU CAN FIGURE IT OUT. I am not too great at this stuff but some things are pretty clear.

I called the VA and they confirmed the contract amount of $230.7 million is for 5 years and they said they arrived at that number based on vendor bids using estimated numbers of patients. This filing is clearly saying ADAT's potential for the 5 years is $122 million - which is over 1/2 of the total awarded contract. 6 companies may be listed on the award, but ADAT appears to be THE major vendor, BY A LOT. Also, one of the major questions I have is that all the PR's and also this filing states the amount is based on the number of units purchased and it also mentions purchase orders from the VA hospitals. No where in any of the releases has it mentioned monthly rental per unit, and we know there is one. I can't remember exactly what Ben said it was, but I seem to recall it was something like $50-60@mo. The VA previously stated in a PR they expected to have 70,000 patients by 2011 and if we are the major vendor, which it appears we are, that means we could be putting out 25 or 30000 units. I am not sure if the stated award includes that monthly rental fee or not, but if it doesn't - that's a ton of money folks -like another $15-20 Mill@ yr or so.

OK, tell me where i am off on this. I figure I must be. One thing for sure tho - we evidently have got a lot bigger piece of the pie than the others. $122 mill out of $230 mill. Since the rest of the pie is divided between 5, it doesn't look like it is even close.Makes you wonder just how good our technology must really be ????

I'm sure some of you can be much more accurate than I am and make more sense of the numbers. I assume at the next CC or the mtg on 5/4 Ben will put definitive numbers to everything and clear up all the guessing, Should be a hulluva mtg.

Romo, always been partial to red. Rating :

ADAT:NASDAQ $1.47 +$.22 $5 Target
Noone knows the Veteran Administration contract is $122 Million OK, all you math geniuses out there, you better take a close look at this filing because I think it says a lot IF YOU CAN FIGURE IT OUT. I am not too great at this stuff but some things are pretty clear.

I called the VA and they confirmed the contract amount of $230.7 million is for 5 years and they said they arrived at that number based on vendor bids using estimated numbers of patients. This filing is clearly saying ADAT's potential for the 5 years is $122 million - which is over 1/2 of the total awarded contract. 6 companies may be listed on the award, but ADAT appears to be THE major vendor, BY A LOT. Also, one of the major questions I have is that all the PR's and also this filing states the amount is based on the number of units purchased and it also mentions purchase orders from the VA hospitals. No where in any of the releases has it mentioned monthly rental per unit, and we know there is one. I can't remember exactly what Ben said it was, but I seem to recall it was something like $50-60@mo. The VA previously stated in a PR they expected to have 70,000 patients by 2011 and if we are the major vendor, which it appears we are, that means we could be putting out 25 or 30000 units. I am not sure if the stated award includes that monthly rental fee or not, but if it doesn't - that's a ton of money folks -like another $15-20 Mill@ yr or so.

OK, tell me where i am off on this. I figure I must be. One thing for sure tho - we evidently have got a lot bigger piece of the pie than the others. $122 mill out of $230 mill. Since the rest of the pie is divided between 5, it doesn't look like it is even close.Makes you wonder just how good our technology must really be ????

I'm sure some of you can be much more accurate than I am and make more sense of the numbers. I assume at the next CC or the mtg on 5/4 Ben will put definitive numbers to everything and clear up all the guessing, Should be a hulluva mtg.

Romo, always been partial to red. Rating :

LUNA finally taking off. following HNSN they own a few million shares
- Cash flow positive.
- Just announced extension to research Agreement with ISRG:NASDAQ
- 8 MM float that is 50% owned by institutions.
- $30 MM market cap
- Traded at $6 share price in 2007 with lower levels of revenue and cash flow.
-Major players in sector (HNSN) have gained up to 200% while LUNA is still under the radar.
- Frequently mentioned as acquisition candidate because of industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.

ZOOG may double nexy week.
ZOOG will announce record sales and profits next week is still trading at a huge discount to COOL and MCZ.

Highlights:

- Profitable.

- 1.9 MM float.

-ZOOG trades at a P/S ratio of 0.52 compared to the Industry average of 2.0 If ZOOG traded at even HALF the sector average it would be $10.

-Based on January 31 guidance, ZOOG will earn between $3.5 MM to $4.5 MM EBITDA for Q4. That translates to between $.50 and $.60 EPS after tax.

-2011 Guidance will be Huge as CEO said 2011 will be transformative year.

ZOOG will announce record sales and profits next week is still trading at a huge discount to COOL and MCZ.

Highlights:

- Profitable.

- 1.9 MM float.

-ZOOG trades at a P/S ratio of 0.52 compared to the Industry average of 2.0 If ZOOG traded at even HALF the sector average it would be $10.

-Based on January 31 guidance, ZOOG will earn between $3.5 MM to $4.5 MM EBITDA for Q4. That translates to between $.50 and $.60 EPS after tax.

-2011 Guidance will be Huge as CEO said 2011 will be transformative year.

ZOOG is next ATEA IMO. Blowout earnings will be reported next week. Tiny 1.5 MM float. Gaminhg has been hottest sectot.
http://finance.yahoo.com/news/Zoo-Entertainment-Expects-to-iw-4185733611.html?x=0&.v=1

ZHNE $2.66 no brainer

-Low float, cash flow positive, turning GAAP profitable in second half of the year.

-Trades at a Price/Sales ratio of 0.6 compared to Industry average of 2.5.

-Traded at $15 - $20 range in 2006.

Major players in sector (ALU, TXCC) have gained up to 300% while ZHNE is still under the radar.

-If you back out the $1.70 per share working capital, ZHNE trades at $.70
http://finance.yahoo.com/q/bs?s=ZHNE+Balance+Sheet&annual

In short, ZHNE has all the ingredients to go much higher in a very short time frame.

$5 very soon.

Next quarter should be a blowout. Defferred revenue now higher than ever.

I believe that another wild and profitable ride is about to begin.
To understand why, you need to understand that Astea’s volatility largely stems from the lumpy nature of its license revenue business. Its typical deal can range from $100,000 to over $1M. Often, the customer pays for the software, but the contract terms don’t allow Astea to recognize the revenue right away. When that happens, deferred revenue jumps and future quarters see the benefit.


Deferred revenue balance

December 31 2009 $4.8 million
June 30 $5.7 million
September 30 $5.6 million
december 31 $6 million

ONSM could be next VTRO. $1.43, 8 million float, turning cash flow positive, in hot space.

http://finance.yahoo.com/q?s=onsm&ql=1

ATEA- increasing backlog:
In the Q3 earnings release ATEA said the backlog of high margin professional services growing. In Friday CC they mentioned again that professional services was getting very busy:

From Q3 Earnings release:
"Accordingly, we have a positive outlook for Q4 and well into 2011. Because of the new global customers we have added this year, as well as the international expansion of existing customers, we are building up a backlog of professional services activity that will have a positive financial impact moving forward."

He did say there is always significant quarter to quarter variation, but that is understandable. If there wasn't it would be $20.
Seems cheap at $5.80 even if they only make $.50 or $.60, competitor CKSW trades at 30 PE.

ATEA is benefiting from the crashing US dollar and boom in sales to Japan and Europe. International sales rose 77% last year.

Good job. I bought at $4, wish I sold but will get back there.

ATEA Due Diligence Summary:
ATEA is up 100% this year, but is still trading at a huge discount.

ATEA announced $.34 EPS in Q4 2010. The CEO said that 2011 will have sustained sales growth and profitability.

ATEA International sales are exploding due to customer growth and the falling U.S. dollar.
2010 international sales increased 77% to $11,155,000.

ATEA trades at a P/S ratio of 0.6 compared to the Industry average of 2.7. If ATEA traded at even HALF the sector average it would be $12.

The most successful U.S. hedge fund, Renaissance Capital, owns ATEA. Renaissance has an army of engineers and MBA's scouring for undervalued stocks.

The workforce management sector is BOOMING, with competitors like CKSW forecasting 20% growth for 2011.

ATEA has slashed costs to the bone. Selling and administrative expenses have fallen 25% from 2007 levels.

ATEA has a tightly held 1.1 Million float. It can move very fast, in 2005 went from $8 to $18 in a month.

In short, ATEA has all the ingredients to go much higher in a very short time frame.

HIGHLIGHTS:

- Profitable.
- 1.1 MM float that is 50% owned by institutions.
- $20 MM market cap
- Traded at $20 share price in 2006 with similar levels of revenue and profits.
-Major players in sector (CKSW) have gained up to 300% while ATEA is still under the radar.
- Frequently mentioned as acquisition candidate because of industry consolidation.
- Company hiring at all worldwide locations due to ramp up in order and backlog growth.

ATEA Blowout results $.34 EPS for quarter
Only 1 MM float $10 tomorrow.
http://finance.yahoo.com/news/Astea-Reports-Full-Year-2010-prnews-3652411722.html?x=0&.v=1

ATEA Blowout results $.34 EPS for quarter
Only 1 MM float $10 tomorrow.
http://finance.yahoo.com/news/Astea-Reports-Full-Year-2010-prnews-3652411722.html?x=0&.v=1

ATEA $4.10 1 Million float could skyrocket on results tomorrow
Turning profitable very strong outlook. This was a $20 stock in 2005.
Reports Third Quarter 2010 Results

For the third quarter ended September 30, 2010, Astea reported revenues of $5.0 million compared to revenues of $4.8 million for the same period in 2009. Net loss for the third quarter was $.5 million or ($.16) per share, compared to a net loss of $.4 million or ($.12) per share for the same period in 2009. License revenues were $.7 million compared to $.4 million in 2009. Total service and maintenance revenues were $ 4.3 million compared to $4.4 million in 2009.

"We are pleased to see an increased level of business activity in Asia Pacific and EMEA. However, the US is still in a slow recovery from the current difficult economic downturn. While it is challenging to control the timing of our larger opportunities, due to their internal approval processes, we have a number of significant opportunities that are at the end of their sales cycle and are expected to close in the fourth quarter," said Zack Bergreen, CEO of Astea International. "Our outlook on future business is bright and growing. We expect to be profitable in the fourth quarter with increasing revenues in both licenses and professional services. The opportunities that we are actively engaged in around the world have significantly increased. Accordingly, we have a positive outlook for Q4 and well into 2011. Because of the new global customers we have added this year, as well as the international expansion of existing customers, we are building up a backlog of professional services activity that will have a positive financial impact moving forward. We have a strong global infrastructure, industry leading solution and a team of domain experts that make us unmatched in the industry today. Our customers and prospects are clearly looking to Astea when it comes to driving a consistent level of service delivery around the world and we are very proud to be their partner for success."

ATEA $4.10 1 Million float could skyrocket on results tomorrow
Turning profitable very strong outlook. This was a $20 stock in 2005.
Reports Third Quarter 2010 Results

For the third quarter ended September 30, 2010, Astea reported revenues of $5.0 million compared to revenues of $4.8 million for the same period in 2009. Net loss for the third quarter was $.5 million or ($.16) per share, compared to a net loss of $.4 million or ($.12) per share for the same period in 2009. License revenues were $.7 million compared to $.4 million in 2009. Total service and maintenance revenues were $ 4.3 million compared to $4.4 million in 2009.

"We are pleased to see an increased level of business activity in Asia Pacific and EMEA. However, the US is still in a slow recovery from the current difficult economic downturn. While it is challenging to control the timing of our larger opportunities, due to their internal approval processes, we have a number of significant opportunities that are at the end of their sales cycle and are expected to close in the fourth quarter," said Zack Bergreen, CEO of Astea International. "Our outlook on future business is bright and growing. We expect to be profitable in the fourth quarter with increasing revenues in both licenses and professional services. The opportunities that we are actively engaged in around the world have significantly increased. Accordingly, we have a positive outlook for Q4 and well into 2011. Because of the new global customers we have added this year, as well as the international expansion of existing customers, we are building up a backlog of professional services activity that will have a positive financial impact moving forward. We have a strong global infrastructure, industry leading solution and a team of domain experts that make us unmatched in the industry today. Our customers and prospects are clearly looking to Astea when it comes to driving a consistent level of service delivery around the world and we are very proud to be their partner for success."

GENE moving $1.88 was $6.9 a few months ago
http://finance.yahoo.com/echarts?s=GENE+Interactive#symbol=GENE;range=3m

Tiny float, profitable, moved a few months ago when it said was introducing new cancer test in U.S.

DEJ:AMEX $.52 oil stock huge news +25%
http://finance.yahoo.com/news/Dejour-Commences-Injection-at-bw-3030037413.html?x=0&.v=1

DEJ going to $.70 today IMO

DSCO no brainer $6 target Most bios with pending drug approval filings have $200 market cap minimim

CYDE: No brainer 30% return on filing.

- CYDE traded in the $3.50 - $4 range prior to announcing late Q3 10Q filing.

- Just annnounced updated financials will be filed before
year-end, no material changes.

-CYDE is an internet security stock growing 188% per year, and is launching a number of new offerings.
CEO said CYDE will turn cash flow positive by year end.

I am in for the no brainer filing pop back to $3.50.
Reminds me of when LUNA filed its late statements, doubled in a few days.

I see $3.50 minimum after uppated financials.

LUNA
Jan 13, 2010 4.31 4.40 3.83 3.95 541,700 3.95
Jan 12, 2010 3.70 5.00 3.52 4.43 1,982,700 4.43
Jan 11, 2010 4.37 4.59 3.41 3.66 1,874,600 3.66
Jan 8, 2010 2.90 4.52 2.74 4.50 1,535,300 4.50
Jan 7, 2010 2.70 2.70 2.50 2.62 54,200 2.62
Jan 6, 2010 2.40 2.70 2.40 2.65 154,100 2.65
Jan 5, 2010 2.20 2.39 2.20 2.36 118,700 2.36

CYDE: No brainer 30% return on filing.

- CYDE traded in the $3.50 - $4 range prior to announcing late Q3 10Q filing.

- Just annnounced updated financials will be filed before
year-end, no material changes.

-CYDE is an internet security stock growing 188% per year, and is launching a number of new offerings.
CEO said CYDE will turn cash flow positive by year end.

I am in for the no brainer filing pop back to $3.50.
Reminds me of when LUNA filed its late statements, doubled in a few days.

I see $3.50 minimum after uppated financials.

LUNA
Jan 13, 2010 4.31 4.40 3.83 3.95 541,700 3.95
Jan 12, 2010 3.70 5.00 3.52 4.43 1,982,700 4.43
Jan 11, 2010 4.37 4.59 3.41 3.66 1,874,600 3.66
Jan 8, 2010 2.90 4.52 2.74 4.50 1,535,300 4.50
Jan 7, 2010 2.70 2.70 2.50 2.62 54,200 2.62
Jan 6, 2010 2.40 2.70 2.40 2.65 154,100 2.65
Jan 5, 2010 2.20 2.39 2.20 2.36 118,700 2.36

FDA Meeting- ARNA will EXPLODE
From recent conference, we know ARNA and its partner will be meeting with the FDA next week to move Locaresing forward.
This will be a major catalayst, similar to ALXA, which rose 22% today on FDA Meeting announcement.


ALXA rose as investor fear that there wouldn't another FDA meeting in the near term has been resolved.

The same thing will happen with ARNA.
Within 45 days there will be resolution
so the dead money fear is gone. Speculators will drive the price up for the coin toss of the FDA's demands.
This combined with OREX approval, will light a fire under ARNA.
See you at $2.50 soon.

HH $.78 +10% going way higher

HH is the cheapest sub $1 stock out there.
Provides health exams for insurers.

-Cash flow positive and profitable.
-Was $4 a few years ago.
-Great balance sheet, no debt.
-Going into strongest seasonal quarter
-Insider buying and stock buyback
-has slashed costs. 2011 will see first full year of lower cost structure.

$1.50 is a slam dunk $2 a layup.

HH $.78 +10% going way higher

HH is the cheapest sub $1 stock out there.
Provides health exams for insurers.

-Cash flow positive and profitable.
-Was $4 a few years ago.
-Great balance sheet, no debt.
-Going into strongest seasonal quarter
-Insider buying and stock buyback
-has slashed costs. 2011 will see first full year of lower cost structure.

$1.50 is a slam dunk $2 a layup.

HH $.78 +10% going way higher

HH is the cheapest sub $1 stock out there.
Provides health exams for insurers.

-Cash flow positive and profitable.
-Was $4 a few years ago.
-Great balance sheet, no debt.
-Going into strongest seasonal quarter
-Insider buying and stock buyback
-has slashed costs. 2011 will see first full year of lower cost structure.

$1.50 is a slam dunk $2 a layup.

NLST gonna rocket tomorrow on bullish CEO comments:

http://www.ocbj.com/news/2010/dec/05/netlist-turnaround-problems-progress/

The Compellant deal, announced last week, “will be a nice chunk of business over the next few years,” Hong said.

Hong sees the tide turning soon for Netlist.
“We will be a vastly different company in terms of the financials a year from now,” he said.